The CooperSurgical owned laboratory where Cells for Life’s samples are stored (CooperSurgical is Cells for Life’s parent company) released their first cord blood sample for experimental regenerative therapy in 2005.¹ This milestone — their first non-transplant...
Planning for a new baby is one of the most exciting times in a parent’s life. It can also be one of the most overwhelming. From choosing your baby’s name to deciding on a pediatrician, it can feel like every little decision could have a big impact on your child’s...
As the year comes to a close, we’re taking a moment to reflect back on the inspiring journeys of our CooperSurgical families over the past year. Hearing their stories reminds us of why we work so hard to spread awareness about the incredible potential of newborn stem...
What if treating extremely preterm babies with their own (i.e., autologous) cord blood stem cells could reduce their increased risk of brain damage and related conditions? Using a patient’s own cord blood stem cells to treat neurological conditions, like cerebral...
The FDA made history in April with its first-ever approval of an expanded cord blood product for use as a primary treatment in hematopoietic stem cell transplants (HSCT) for certain blood cancers in adults and children 12 years of age and older.1 Why is cord...
A steady stream of families contact our team every year, requesting the release of their stored newborn stem cell samples for use in stem cell transplant procedures or regulated experimental protocols in regenerative medicine. We are proud to provide newborn stem cell...
